Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,061 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease.
Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T; ADJUST study group. Tanaka H, et al. Among authors: yoshino t. J Gastroenterol Hepatol. 2018 May;33(5):1031-1038. doi: 10.1111/jgh.14034. Epub 2018 Mar 15. J Gastroenterol Hepatol. 2018. PMID: 29087616
Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort Study.
Kobayashi T, Hishida A, Tanaka H, Nuki Y, Bamba S, Yamada A, Fujii T, Shinzaki S, Yokoyama Y, Yoshida A, Ozeki K, Ashizuka S, Kamata N, Nanjo S, Kakimoto K, Nakamura M, Matsui A, Yamauchi R, Takahashi S, Tomizawa T, Yoshino T, Hibi T. Kobayashi T, et al. Among authors: yoshino t. Inflamm Bowel Dis. 2017 Dec;23(12):2245-2251. doi: 10.1097/MIB.0000000000001276. Inflamm Bowel Dis. 2017. PMID: 29084079
Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease.
Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M, Tanaka H, Ozeki K, Takahashi S, Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T. Shinzaki S, et al. Among authors: yoshino t. Intest Res. 2018 Oct;16(4):609-618. doi: 10.5217/ir.2018.00044. Epub 2018 Oct 10. Intest Res. 2018. PMID: 30301329 Free PMC article.
Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease.
Yoshida A, Kamata N, Yamada A, Yokoyama Y, Omori T, Fujii T, Hayashi R, Kinjo T, Matsui A, Fukata N, Takahashi S, Sakemi R, Ogata N, Ashizuka S, Bamba S, Ooi M, Kanmura S, Endo K, Yoshino T, Tanaka H, Morizane T, Shinzaki S, Kobayashi T. Yoshida A, et al. Among authors: yoshino t. Inflamm Intest Dis. 2019 Apr;3(4):167-172. doi: 10.1159/000495035. Epub 2019 Feb 6. Inflamm Intest Dis. 2019. PMID: 31111032 Free PMC article.
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Kobayashi T, et al. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):429-437. doi: 10.1016/S2468-1253(21)00062-5. Epub 2021 Apr 20. Lancet Gastroenterol Hepatol. 2021. PMID: 33887262 Clinical Trial.
Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study-CAPITAL (Cohort and Practice for IBD total management in Kyoto-Shiga Links) study I.
Yoshino T, Nakase H, Takagi T, Bamba S, Okuyama Y, Kawamura T, Oki T, Obata H, Kawanami C, Katsushima S, Kusaka T, Tsujikawa T, Naito Y, Andoh A, Kogawa T. Yoshino T, et al. BMJ Open Gastroenterol. 2016 Nov 24;3(1):e000122. doi: 10.1136/bmjgast-2016-000122. eCollection 2016. BMJ Open Gastroenterol. 2016. PMID: 27933204 Free PMC article.
2,061 results